R
Romain Coriat
Researcher at Paris Descartes University
Publications - 237
Citations - 3933
Romain Coriat is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 29, co-authored 176 publications receiving 3096 citations. Previous affiliations of Romain Coriat include Cochin University of Science and Technology & Sorbonne.
Papers
More filters
Journal ArticleDOI
Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
Olivier Mir,Romain Coriat,Benoit Blanchet,Jean-Philippe Durand,Pascaline Boudou-Rouquette,Judith Michels,Stanislas Ropert,Michel Vidal,Stanislas Pol,Stanislas Chaussade,François Goldwasser +10 more
TL;DR: Among cirrhotic Child Pugh A patients with advanced HCC, sarcopenia predicts sorafenib exposure and the occurrence of DLT within the first month of treatment.
Journal ArticleDOI
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial
Jean-Philippe Durand,Gael Deplanque,Vincent Montheil,J.M. Gornet,Florian Scotté,Olivier Mir,Anatole Cessot,Romain Coriat,Eric Raymond,Emmanuel Mitry,P. Herait,Y. Yataghene,François Goldwasser +12 more
TL;DR: Venlafaxine has clinical activity against oxaliplatin-induced acute neurosensory toxicity and the primary end point was the percentage of patients with a 100% relief under treatment.
Journal ArticleDOI
Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.
Jean-Emmanuel Bibault,Philippe Giraud,Martin Housset,Catherine Durdux,Julien Taieb,Anne Berger,Romain Coriat,Romain Coriat,Stanislas Chaussade,Stanislas Chaussade,Bertrand Dousset,B. Nordlinger,Anita Burgun +12 more
TL;DR: The DNN model correctly predicted complete response after neo-adjuvant rectal chemoradiotherapy in 80% of the patients of this multicenter cohort, which may help to identify patients who would benefit from a conservative treatment, rather than a radical resection.
Journal ArticleDOI
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Lysiane Marthey,Antonio Sa-Cunha,Jean-Frédéric Blanc,Mélanie Gauthier,Adèle Cueff,Eric Francois,Isabelle Trouilloud,David Malka,Jean-Baptiste Bachet,Romain Coriat,Eric Terrebonne,C. De La Fouchardiere,Sylvain Manfredi,D. Solub,Cedric Lecaille,A. Thirot Bidault,Franck Carbonnel,Julien Taieb +17 more
TL;DR: First-line FOLFIRINOX for LAPA seems to be effective and have a manageable toxicity profile, and promising results will have to be confirmed in a phase III randomized trial.
Journal ArticleDOI
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal,Simon Pernot,David Tougeron,Claire Arbaud,Anne Thirot Bidault,Christelle De La Fouchardiere,Pascal Hammel,Thierry Lecomte,Johann Dreanic,Romain Coriat,Jean-Baptiste Bachet,Olivier Dubreuil,Lysiane Marthey,Laetitia Dahan,Belinda Tchoundjeu,Christophe Locher,Céline Lepère,Franck Bonnetain,Julien Taieb +18 more
TL;DR: Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort is presented.